ReviewAdvances in experimental medicine and biology2026
Applications of Metabolomics in the Development of Biomedicine and Biotechnology.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The cervicovaginal gut microbiota axis as a key determinant of systemic physiology.Gut microbes · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolomics has emerged as a powerful discipline for capturing dynamic biochemical states and linking molecular processes to human health, disease, and biotechnology. This chapter explores the evolution of metabolomics from early profiling efforts to its current integration with advanced analytical platforms, computational biology, and precision medicine. We highlight how targeted and untargeted metabolomic strategies have advanced biomarker discovery, clarified disease mechanisms, and informed the development of personalized therapies in cancer, cardiovascular disease, diabetes, and other conditions. The role of pharmacometabolomics in refining drug response predictions and guiding therapeutic decisions is also examined. Beyond biomedicine, metabolomics drives innovation in biotechnology, synthetic biology, and bio-based production, while emerging tools such as single-cell metabolomics and machine learning continue to expand its scope. By directly tracing metabolic fluxes and engineering new pathways, metabolomics is becoming a practical engine for designing microbes, optimizing bioprocesses, and accelerating drug discovery.
Indexed as
Identifiers
42071157What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.